AR061478A1 - Compuesto triciclico y composicion farmaceutica - Google Patents

Compuesto triciclico y composicion farmaceutica

Info

Publication number
AR061478A1
AR061478A1 ARP070102638A ARP070102638A AR061478A1 AR 061478 A1 AR061478 A1 AR 061478A1 AR P070102638 A ARP070102638 A AR P070102638A AR P070102638 A ARP070102638 A AR P070102638A AR 061478 A1 AR061478 A1 AR 061478A1
Authority
AR
Argentina
Prior art keywords
optionally
substituents
group
ring
possesses
Prior art date
Application number
ARP070102638A
Other languages
English (en)
Inventor
O Uchikawa
T Koike
Y Hoashi
T Takal
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR061478A1 publication Critical patent/AR061478A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

La presente provee un compuesto tricíclico y una composicion farmacéutica. Estos compuestos resultan de utilidad como agentes para la profilaxis o tratamiento de enfermedades relacionadas con la accion de la melatonina, particularmente relacionadas con la alteracion del ritmo del sueno. Reivindicacion 1: Un compuesto caracterizado por la formula (1) en la cual R1 es un grupo hidrocarburo que opcionalmente posee uno o más sustituyentes, un grupo amino que opcionalmente posee uno o más sustituyentes, un grupo hidroxi que opcionalmente posee un sustituyente o un grupo heterocíclico que opcionalmente posee uno o más sustituyentes; R5 es un átomo de hidrogeno, un átomo halogeno, un hidrocarburo que opcionalmente posee uno o sustituyentes, un grupo amino que opcionalmente posee uno o más sustituyentes, un grupo hidroxi que opcionalmente posee un sustituyente o un grupo mercapto que opcionalmente un sustituyente; R6 es un átomo de hidrogeno o un grupo hidrocarburo que opcionalmente posee uno o más sustituyentes; X es un átomo de oxígeno o un átomo de azufre; m es 0, 1 o 2;el anillo A es un anillo de 5 miembros que opcionalmente posee uno o más sustituyentes; el anillo B es un anillo de 6 miembros opcionalmente con uno o más sustituyentes; el anillo C es un anillo de 5 miembros que opcionalmente posee uno o más sustituyentes; en tanto -------- muestra un enlace simple o un enlace doble, o sal del mismo.
ARP070102638A 2006-06-19 2007-06-15 Compuesto triciclico y composicion farmaceutica AR061478A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006168518 2006-06-19

Publications (1)

Publication Number Publication Date
AR061478A1 true AR061478A1 (es) 2008-08-27

Family

ID=38519675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102638A AR061478A1 (es) 2006-06-19 2007-06-15 Compuesto triciclico y composicion farmaceutica

Country Status (36)

Country Link
US (5) US8030337B2 (es)
EP (1) EP2029561B1 (es)
JP (1) JP5222737B2 (es)
KR (1) KR101442274B1 (es)
CN (1) CN101506181B (es)
AR (1) AR061478A1 (es)
AU (1) AU2007261953B2 (es)
BR (1) BRPI0713743C1 (es)
CA (1) CA2655753C (es)
CL (1) CL2007001779A1 (es)
CO (1) CO6150175A2 (es)
CR (1) CR10524A (es)
CY (1) CY1115729T1 (es)
DK (1) DK2029561T3 (es)
ES (1) ES2523410T3 (es)
GE (1) GEP20125392B (es)
HK (1) HK1130049A1 (es)
HR (1) HRP20141046T1 (es)
IL (1) IL195639A0 (es)
JO (1) JO2999B1 (es)
MA (1) MA30523B1 (es)
ME (2) ME00582A (es)
MX (1) MX2008015842A (es)
MY (1) MY158069A (es)
NO (1) NO341739B1 (es)
NZ (1) NZ574037A (es)
PE (1) PE20080941A1 (es)
PL (1) PL2029561T3 (es)
PT (1) PT2029561E (es)
RS (1) RS53616B1 (es)
RU (1) RU2456278C2 (es)
SI (1) SI2029561T1 (es)
TW (1) TWI402261B (es)
UA (1) UA99104C2 (es)
WO (1) WO2007148808A1 (es)
ZA (1) ZA200900151B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
KR20090095666A (ko) * 2006-12-28 2009-09-09 다케다 야쿠힌 고교 가부시키가이샤 삼환 화합물 및 이의 약학적 용도
CN103450111B (zh) * 2013-09-04 2015-07-08 温州大学 一种苯并噻唑杂环化合物的绿色合成方法
US20160253891A1 (en) * 2015-02-27 2016-09-01 Elwha Llc Device that determines that a subject may contact a sensed object and that warns of the potential contact
CA3010804A1 (en) * 2016-01-08 2017-07-13 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for autism spectrum disorder
KR20180100627A (ko) * 2016-01-08 2018-09-11 다케다 야쿠힌 고교 가부시키가이샤 섬망의 예방 또는 치료제
BR112019007964A2 (pt) 2016-10-19 2019-07-02 Monsanto Technology Llc composições e métodos para alterar a floração e arquitetura vegetal para aprimorar o potencial de rendimento

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292226C (en) * 1986-01-16 1991-11-19 Terumi Hachiya Indenothiazole derivative and process for preparing the same
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5654325A (en) 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
FR2725985B1 (fr) 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19502895A1 (de) 1995-01-31 1996-08-01 Merck Patent Gmbh 4-Mercapto-benzoylguanidin-Derivate
US5753709A (en) 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5596019A (en) 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
CA2176854A1 (en) 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
FR2742153B1 (fr) 1995-12-12 1998-02-13 Innothera Lab Sa Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
CN100441574C (zh) 1996-03-08 2008-12-10 武田药品工业株式会社 三环化合物及其制备和用途
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
SE9802360D0 (sv) * 1998-07-01 1998-07-01 Wikstroem Hakan Vilhelm New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins ((basic)-N-substituted and (basic)-N,N-disubstituted derivatives of 2,6-diamino-thiazolo(4,5-f)indan and 2,7-di-amino-thiazolo(4,5-g)tetralin
AU6595100A (en) * 1999-08-20 2001-03-19 Takeda Chemical Industries Ltd. Percutaneous absorption agents
WO2002040054A1 (fr) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Preparation pharmaceutique contenant de la copolyvidone
JP3633895B2 (ja) * 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
US20060223877A1 (en) 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica

Also Published As

Publication number Publication date
ME00582A (en) 2011-12-20
CO6150175A2 (es) 2010-04-20
MY158069A (en) 2016-08-30
US20140011849A1 (en) 2014-01-09
PT2029561E (pt) 2014-11-12
RU2456278C2 (ru) 2012-07-20
AU2007261953A1 (en) 2007-12-27
BRPI0713743A2 (pt) 2012-11-06
CL2007001779A1 (es) 2008-01-04
EP2029561A1 (en) 2009-03-04
PL2029561T3 (pl) 2015-03-31
ZA200900151B (en) 2010-03-31
US20110196003A1 (en) 2011-08-11
US8552037B2 (en) 2013-10-08
JO2999B1 (ar) 2016-09-05
HRP20141046T1 (hr) 2014-12-19
AU2007261953B2 (en) 2012-11-08
CY1115729T1 (el) 2017-01-25
CN101506181B (zh) 2011-12-07
US20090182023A1 (en) 2009-07-16
IL195639A0 (en) 2009-09-01
US8030337B2 (en) 2011-10-04
NO341739B1 (no) 2018-01-15
US8236837B2 (en) 2012-08-07
RS53616B1 (en) 2015-04-30
US8349879B2 (en) 2013-01-08
BRPI0713743B8 (pt) 2020-05-19
CN101506181A (zh) 2009-08-12
MA30523B1 (fr) 2009-06-01
TWI402261B (zh) 2013-07-21
WO2007148808A1 (en) 2007-12-27
NZ574037A (en) 2011-10-28
KR20090023701A (ko) 2009-03-05
TW200815376A (en) 2008-04-01
US20130079374A1 (en) 2013-03-28
CA2655753C (en) 2015-08-04
ME01998B (me) 2015-05-20
US8895591B2 (en) 2014-11-25
KR101442274B1 (ko) 2014-09-22
HK1130049A1 (en) 2009-12-18
ES2523410T3 (es) 2014-11-25
JP5222737B2 (ja) 2013-06-26
MX2008015842A (es) 2009-01-09
NO20090234L (no) 2009-02-12
GEP20125392B (en) 2012-02-10
SI2029561T1 (sl) 2014-11-28
PE20080941A1 (es) 2008-09-04
US20110190361A1 (en) 2011-08-04
CA2655753A1 (en) 2007-12-27
CR10524A (es) 2009-01-27
DK2029561T3 (da) 2014-11-10
RU2009101299A (ru) 2010-07-27
EP2029561B1 (en) 2014-08-13
BRPI0713743B1 (pt) 2020-03-17
JP2009541202A (ja) 2009-11-26
BRPI0713743C1 (pt) 2021-05-25
UA99104C2 (uk) 2012-07-25

Similar Documents

Publication Publication Date Title
ECSP099330A (es) Compuesto de indol
AR061478A1 (es) Compuesto triciclico y composicion farmaceutica
PE20190711A1 (es) N-(fenils ulfonil) benzamidas y compuestos relacionados como inhibidores de bcl-2
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
GT200800189A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
ECSP11010880A (es) Compuestos orgánicos
UY33001A (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
AR066962A1 (es) Compuesto heterociclico fusionado
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
CL2011002182A1 (es) Compuestos heterociclicos que contienen 2 o mas heterociclos con n como heteroatomos del ciclo, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso en el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras enfermedades..
UY32858A (es) Derivados de (tio)morfolina como moduladores de sip
CL2011002221A1 (es) Compuestos heterociclicos con n, o y s como heteroatomos del ciclo, sustituidos con otros heterociclos, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica, utiles en el tratatmiento de diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras.
NI201100117A (es) Antagonistas de 4 -- azetidinil - 1 - heteroaril - ciclohexanol del ccr2.
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
AR070874A1 (es) Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer.
EA200970642A1 (ru) Трициклическое соединение и его фармацевтическое применение
ATE548371T1 (de) Tricyclische verbindung und deren medizinische verwendung
PE20090295A1 (es) Derivados de espirociclopropilpiperidina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee